Para a preparação EUDR, o código SH/NC 30021091 está classificado como fora do âmbito.
Haemoglobin, blood globulins and serum globulins(2012-2016);Haemoglobin, blood globulins and serum globulins(2002-2011);Haemoglobin, blood globulins and serum globulins(1988-2001) O motor de âmbito indexado devolve Out of scope para este código. No Annex I scope match was found for this indexed CN code.
Porque é que esta página de referência dá essa resposta.
- Descrição do código
- Haemoglobin, blood globulins and serum globulins(2012-2016);Haemoglobin, blood globulins and serum globulins(2002-2011);Haemoglobin, blood globulins and serum globulins(1988-2001)
- Base no anexo I
- Sem entrada direta no anexo I
- Base da fonte
- Regulation (EU) 2023/1115 Annex I and CN 2026 index
Linhas ascendentes, descendentes e próximas.
A vista de biblioteca destina-se à navegação de referência. Use o verificador quando quiser executar outro código como ação.
30produtos farmacêuticosout3002human blood; animal blood prepared for therapeutic, prophylactic or diagnostic uses; antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes; vaccines, toxins, cultures of micro-organisms (excl. yeasts) and similar productsout300210antisera and other blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processesout30021010antisera(2012-2016);antisera(2002-2011);antisera(1988-2001)out30021095blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of human blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(2012-2012);blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of human blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(2002-2011);blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of human blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(1988-2001)out30021098blood fractions and immunological products, whether or not modified or obtained by means of biotechnological processes (excl. antisera, haemoglobin, blood globulins and serum globulins)out30021099blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of animal blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(2012-2012);blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of animal blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(2002-2011);blood fractions and modified immunological products, whether or not obtained by means of biotechnological processes, of animal blood (excl. antisera, haemoglobin, blood globulins and serum globulins)(1988-2001)out
O que isto significa para a preparação.
Esta linha não desencadeia diretamente a recolha de provas no resultado de âmbito atual.
Regulation (EU) 2023/1115 Annex I — relevant productsobtido em 2026-08-06Commission Delegated Regulation (EU) 2026/2102 amending Annex I to Regulation (EU) 2023/1115obtido em 2026-09-24Eurostat Comext Combined Nomenclature codelist (CXT_NC v11.0)obtido em 2026-08-06Eurostat Comext partner country codelist (CXT_FREE_ISO)obtido em 2026-08-06Eurostat Comext DS-045409 — EU trade since 1988 by HS2-4-6 and CN8obtido em 2026-08-06Commission Implementing Regulation (EU) 2025/1093 — country benchmarkingobtido em 2026-08-06Regulation (EU) 2025/2650 amending Regulation (EU) 2023/1115 as regards certain obligations of operators and tradersobtido em 2025-12-26Commission Implementing Regulation (EU) 2026/1565 amending Implementing Regulation (EU) 2024/3084 (EUDR information system)obtido em 2026-08-08